The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Daiichi Sankyo Exits Global Hybrid Biz Model, Now Focuses on Innovation
May 18, 2015
-
REGULATORY PAFSC Second Committee to Discuss Gilead’s Combination Hepatitis C Treatment on May 28
May 15, 2015
-
REGULATORY Chuikyo Reps Discuss HTA, Re-Pricing as Sovaldi Lands in Japan
May 14, 2015
-
REGULATORY Sovaldi’s 5 Million Yen Price Tag OK’d for 12-Week Regimen, Listing on May 20
May 13, 2015
-
BUSINESS Ono to Expand Cancer-Specialized Rep Force to 150 by October Aiming for Additional Indications for Opdivo
May 13, 2015
-
BUSINESS Astellas Earnings Buoyant on Xtandi, Overseas Sales Offset Japan Fall
May 12, 2015
-
REGULATORY Chuikyo to Discuss Listing of Gilead’s Sovaldi on May 13; Listing Could Take Place This Month
May 11, 2015
-
REGULATORY 10-Year Reexamination Period Possible for Repositioned Drugs under Sakigake System: Official
May 8, 2015
-
ACADEMIA MHLW-Funded Study Calls for Use-Based Development Plans for Combination Drugs
May 7, 2015
-
BUSINESS Nichi-Iko Most Favored Maker of Plavix Generics: Survey
May 1, 2015
-
BUSINESS Daiichi Sankyo Cuts FY2014 Forecasts on Write-Off Loss Tied to Zelboraf
April 30, 2015
-
REGULATORY MOF Presses for 80% Generic Share Target by FY2017
April 28, 2015
-
REGULATORY Number of Topics Discussed by PAFSC Second Committee Exceeds that of First Committee for 1st Time in 10 Years: Jiho Tally
April 28, 2015
-
REGULATORY AMED, JPMA Discussing Joint Use of Compounds, with Policy Announcement Expected in Early June: Dr Suematsu of AMED
April 27, 2015
-
BUSINESS Sumitomo Dainippon Faces Dim Prospects for Lurasidone Filing in Japan
April 27, 2015
-
REGULATORY LDP Weighs Clinical Development Infrastructure Utilizing Patient Registry
April 24, 2015
-
REGULATORY MHLW Official Jo Hints at Possible Move-Up of Generic Roadmap
April 23, 2015
-
BUSINESS Ono Seeks Lung Cancer Indication for Opdivo in Japan
April 23, 2015
-
BUSINESS Sales Rep Survey - Part 1: Decreases in Reps Prominent in Major Firms, Is Field Force Strategy at Turning Point?
April 22, 2015
-
BUSINESS Nissan Chemical Loses Livalo Patent Suits against 8 Firms
April 21, 2015
ページ
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…